Erratum: BRCA1 polymorphisms and breast cancer epidemiology in the western new york exposures and breast cancer (WEB) study [(2013)] doi: 10.1002/gepi.21730;BRCA1 Polymorphisms and Breast Cancer Epidemiology in the Western New York Exposures and Breast Cancer (WEB) Study

Genetic Epidemiology

Volumn 37, Issue 5, 2013, Pages 504-511

  Ricks Santi, Luisel J ^a   Nie, Jing ^b   Marian, Catalin ^c   Ochs Balcom, Heather M ^b   Trevisan, Maurizio ^d   Edge, Stephen B ^e   Freudenheim, Jo L ^b   Shields, Peter G ^c  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NEVADA   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

BRCA1; Breast cancer; Gene environment; Haplotypes; Polymorphisms

Indexed keywords

BRCA1 PROTEIN; HORMONE RECEPTOR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; BREAST DISEASE; CANCER EPIDEMIOLOGY; CANCER RISK; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES;

EID: 84879184670     PISSN: 07410395     EISSN: 10982272     Source Type: Journal    
DOI: 10.1002/gepi.21770     Document Type: Erratum

References (77)

1. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA and others. 1996. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276(18):1494-1501.
2. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J. 2008. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev 17(1):15-26.
3. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG and others. 1999. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 59(8):2011-2017.
4. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. 2008. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282-4288.
5. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265.
6. Beral V. 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419-427.
7. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D. 2008. How basal are triple-negative breast cancers? Int J Cancer 123(1):236-240.
8. Bertwistle D, Ashworth A. 1998. Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev 8(1):14-20.
9. Bissonauth V, Shatenstein B, Fafard E, Maugard C, Robidoux A, Narod S, Ghadirian P. 2009. Weight history, smoking, physical activity and breast cancer risk among French-Canadian women non-carriers of more frequent BRCA1/2 mutations. J Cancer Epidemiol 2009:748367.
10. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Trevisan M and others. 2010. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21(9):1503-1512.
11. Brunhuber T, Haybaeck J, Schafer G, Mikuz G, Langhoff E, Saeland S, Lebecque S, Romani N, Obrist P. 2008. Immunohistochemical tracking of an immune response in mammary Paget's disease. Cancer Lett 272(2):206-220.
12. Carey L, Winer E, Viale G, Cameron D, Gianni L. 2010. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683-692.
13. Cox DG, Kraft P, Hankinson SE, Hunter DJ. 2005. Haplotype analysis of common variants in the BRCA1 gene and risk of sporadic breast cancer. Breast Cancer Res. 7(2):R171-R175.
14. Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre C, McGuffog L, Healey S and others. 2011. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet 20(23):4732-4747.
15. Dombernowsky SL, Weischer M, Freiberg JJ, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. 2009. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 18(8):2339-2342.
16. Dunning AM, Chiano M, Smith NR, Dearden J, Gore M, Oakes S, Wilson C, Stratton M, Peto J, Easton D and others. 1997. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet 6(2):285-289.
17. Dupont WD, Plummer WD, Jr. 1990. Power and sample size calculations: a review and computer program. Control Clin Trials 11(2):116-128.
18. Dupont WD, Plummer WD, Jr. 1998. Power and sample size calculations for studies involving linear regression. Control Clin Trials 19(6):589-601.
19. Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, Simard J. 1996. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet 5(6):835-842.
20. Easton DF, Ford D, Bishop DT. 1995. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56(1):265-271.
21. Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PD, Whittemore AS, Haile RW. 2004. Breast cancer risks for BRCA1/2 carriers. Science 306(5705):2187-2191.
22. Faraglia B, Chen SY, Gammon MD, Zhang Y, Teitelbaum SL, Neugut AI, Ahsan H, Garbowski GC, Hibshoosh H, Lin D and others. 2003. Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis 24(4):719-725.
23. Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES, Hassan MM, Li D. 2002. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 23(2):301-306.
24. Foulkes WD, Rosenblatt J, Chappuis PO. 2001. The contribution of inherited factors to the clinicopathological features and behavior of breast cancer. J Mammary Gland Biol Neoplasia 6(4):453-465.
25. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482-1485.
26. Foulkes WD, Smith IE, Reis-Filho JS. 2010. Triple-negative breast cancer. N Engl J Med 363(20):1938-1948.
27. Freedman ML, Penney KL, Stram DO, Riley S, Kean-Cowdin R, Le ML, Altshuler D, Haiman CA. 2005. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk. Cancer Res 65(16):7516-7522.
28. Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C and others. 2009. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Res Treat 114(1):127-135.
29. Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI. 2002. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 62(5):1481-1488.
30. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L and others. 2006. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 7:96.
31. Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T. 2004. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 90(10):2002-2005.
32. Lachapelle J, Foulkes WD. 2011. Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol 18(4):161-164.
33. Lakhani SR, Van V, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. 2002. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310-2318.
34. Lecarpentier J, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Caron O, Fricker JP, Gladieff L, Faivre L, Sobol H and others. 2011. Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Res Treat 130(3):927-938.
35. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750-2767.
36. Li D, Wang M, Dhingra K, Hittelman WN. 1996. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res 56(2):287-293.
37. Liede A, Karlan BY, Narod SA. 2004. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735-742.
38. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. 1998. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 29(10):1140-1144.
39. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, Lenoir GM, Venezia ND. 2002. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 21(44):6729-6739.
40. Manders P, Pijpe A, Hooning MJ, Kluijt I, Vasen HF, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer H, Ausems MG, van Os TA and others. 2011. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat 126(1):193-202.
41. Mangia A, Chiriatti A, Tommasi S, Menolascina F, Petroni S, Zito FA, Simone G, Schittulli F, Paradiso A. 2009. BRCA1 expression and molecular alterations in familial breast cancer. Histol Histopathol 24(1):69-76.
42. McCann SE, Ip C, Ip MM, McGuire MK, Muti P, Edge SB, Trevisan M, Freudenheim JL. 2004. Dietary intake of conjugated linoleic acids and risk of premenopausal and postmenopausal breast cancer, Western New York Exposures and Breast Cancer Study (WEB Study). Cancer Epidemiol Biomarkers Prev 13(9):1480-1484.
43. Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M, Kraft HG. 2004. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90(10):1989-1994.
44. Miller MD, Marty MA, Broadwin R, Johnson KC, Salmon AG, Winder B, Steinmaus C. 2007. The association between exposure to environmental tobacco smoke and breast cancer: a review by the California Environmental Protection Agency. Prev Med 44(2):93-106.
45. Ng PC, Henikoff S. 2001. Predicting deleterious amino acid substitutions. Genome Res. 11(5):863-874.
46. Ng PC, Henikoff S. 2003. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13):3812-3814.
47. Ng PC, Henikoff S. 2006. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genom Hum Genet 7:61-80.
48. Olopade OI, Grushko T. 2001. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344(26):2028-2029.
49. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C and others. 2003. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9(10 Pt 1):3606-3614.
50. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA and others. 2000. Molecular portraits of human breast tumours. Nature 406(6797):747-752.
51. Ramensky V, Bork P, Sunyaev S. 2002. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30(17):3894-3900.
52. Ray H, Suau F, Vincent A, Dalla N. 2009. Cell cycle regulation of the BRCA1/acetyl-CoA-carboxylase complex. Biochem Biophys Res Commun 378(3):615-619.
53. Rebbeck TR, Mitra N, Domchek SM, Wan F, Friebel TM, Tran TV, Singer CF, Tea MK, Blum JL, Tung N and others. 2011. Modification of BRCA1-associated breast and ovarian cancer risk by BRCA1-interacting genes. Cancer Res 71(17):5792-5805.
54. Renehan AG, Frystyk J, Flyvbjerg A. 2006a. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17(8):328-336.
55. Renehan AG, Harvie M, Howell A. 2006b. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 13(2):273-278.
56. Ricks-Santi LJ, Sucheston LE, Yang Y, Freudenheim JL, Isaacs CJ, Schwartz MD, Dumitrescu RG, Marian C, Nie J, Vito D and others. 2011. Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk. BMC Cancer 11:278.
57. Rios J, Puhalla S. 2011. PARP inhibitors in breast cancer: BRCA and beyond. Oncol (Williston.Park) 25(11):1014-1025.
58. Rossouw JE. 2002. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 53(3):550-557.
59. Schnyder S, Du NT, Le HB, Singh S, Loredo GA, Vaughan AT. 2009. Estrogen treatment induces MLL aberrations in human lymphoblastoid cells. Leuk Res 33(10):1400-1404.
60. Sehl ME, Langer LR, Papp JC, Kwan L, Seldon JL, Arellano G, Reiss J, Reed EF, Dandekar S, Korin Y and others. 2009. Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer. Clin Cancer Res 15(6):2192-2203.
61. Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Falcini F, Strada M, Morini N, Naldoni C, Paradiso A and others. 2008. Disease family history and modification of breast cancer risk in common BRCA2 variants. Oncol Rep 19(3):783-786.
62. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. 2012. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 40(W1):W452-W457.
63. Sinilnikova OM, Ginolhac SM, Magnard C, Leone M, Anczukow O, Hughes D, Moreau K, Thompson D, Coutanson C, Hall J and others. 2004. Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 25(12):2417-2424.
64. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS and others. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869-10874.
65. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S and others. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418-8423.
66. Soucek P, Borovanova T, Pohlreich P, Kleibl Z, Novotny J. 2007. Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study. Breast Cancer Res Treat 103(2):219-224.
67. Stephens M, Donnelly P. 2003. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73(5):1162-1169.
68. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978-989.
69. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. 2010. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 120(3):727-736.
70. Thompson D, Easton D. 2002a. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11(4):329-336.
71. Thompson D, Easton DF. 2002b. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358-1365.
72. Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, Calistri D and others. 2005. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res 578(1-2):395-405.
73. Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A. 2008. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 644(1-2):64-70.
74. Tsutsui T, Tamura Y, Yagi E, Barrett JC. 2000. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int J Cancer 86(1):8-14.
75. Wang Q, Zhang H, Fishel R, Greene MI. 2000. BRCA1 and cell signaling. Oncogene 19(53):6152-6158.
76. Zhang XH, Chasin LA. 2004. Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 18(11):1241-1250.
77. Zhang XH, Kangsamaksin T, Chao MS, Banerjee JK, Chasin LA. 2005. Exon inclusion is dependent on predictable exonic splicing enhancers. Mol Cell Biol 25(16):7323-7332.